Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at BMO Biopharma Day: Spotlight on Rare Disease and Ophthalmology (Virtual) Transcript

Jun 22, 2021 / 04:00PM GMT
Release Date Price: $37.69 (+2.11%)
Gary Jay Nachman
BMO Capital Markets Equity Research - Analyst

Hi, everyone. I'm Gary Nachman, the biopharma analyst at BMO, and we're very excited to have Eric Swayze, Head of Research at Ionis with us.

Ionis is a great platform in antisense technology with a very robust portfolio in neurology and cardiovascular disease and has been a major player in rare disease for a long time. So really great to have you here, Eric, to chat with us. Thanks for being here.

Eric E. Swayze
Ionis Pharmaceuticals, Inc. - EVP of Research

Great. I'm happy to be here and join you, Gary. Thanks for the opportunity to chat.

Questions & Answers

Gary Jay Nachman;Eric E. Swayze
BMO Capital Markets Equity Research - Analyst;

Okay. Great. So maybe you can start by just giving a brief overview of the company's antisense technology and just the flexibility that you have to modulate all different types of RNA. So how broad that technology could take you and has it taken you with your pipeline?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot